Novo Nordisk has found a buyer for cell therapy technologies dropped in its retreat from the modality. Aspect Biosystems has ...

Aspect will acquire rights from Novo Nordisk to stem cell-derived islet cell and hypoimmune cell engineering technologies.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects healthy upside for Novo Nordisk stock through ...

Danish drugmaker Novo Nordisk and Canada-based privately held Aspect Biosystems said on Tuesday they have struck a ...

Novo Nordisk Foundation grants DKK 5.5 billion to elevate innovation in Denmark and Europe ...

The past couple of years have been challenging for the company. But this could be the beginning of a new chapter.

Novo Nordisk's Wegovy weight-loss pill has made an "encouraging" start after its launch this month, analysts said on Friday ...

Partnership evolution includes strategic integration of select Novo Nordisk technologies into Aspect BiosystemsAspect will ...

Why economic leverage beats military pressure on Greenland, and how Denmark’s exposure through Novo Nordisk makes trade tools ...

Novo Nordisk A/S (NVO) kicked off 2026 with a major milestone: the U.S. launch of the Wegovy weight-loss pill. This marks the ...

The Novo Nordisk Foundation is investing 5.5 billion Danish kroner ($860 million) in the BioInnovation Institute (BII) to help scale up more homegrown biotechs and deep tech companies. | The Novo ...

The iShares MSCI Denmark ETF is rated a buy, supported by Denmark’s strong fundamentals and macroeconomic tailwinds. Learn ...